Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Eurofins Scientific S.E.    ERF   FR0000038259

EUROFINS SCIENTIFIC S.E.

(ERF)
  Report  
Delayed Quote. Delayed Euronext Paris - 06/26 11:36:35 am
376.6 EUR   +1.62%
06/03EUROFINS SCIENTIFIC S E : ad hoc press release
PU
03/05EUROPE : European shares eke out in directionless choppy session
RE
03/05GLOBAL MARKETS LIVE : Target, Traton, Nordea, Purdue…
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Eurofins Scientific S.E. : A technical turn-around configuration

share with twitter share with LinkedIn share with facebook
share via e-mail
01/09/2019 | 02:45am EDT
long trade
Stop-loss triggered
Entry price : 357.2€ | Target : 420€ | Stop-loss : 310€ | Potential : 17.58%
The technical chart pattern of Eurofins Scientific S.E. shares shows signs of a medium term reversal, which speaks in favor of opening new long positions.
Investors have an opportunity to buy the stock and target the € 420.
Chart EUROFINS SCIENTIFIC S.E.
Duration : Period :
Eurofins Scientific S.E. Technical Analysis Chart | MarketScreener
Full-screen chart
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • In a short-term perspective, the company has interesting fundamentals.

Strengths
  • Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 62% by 2020.
  • The company returns high margins, thereby supporting business profitability.
  • The group usually releases upbeat results with huge surprise rates.
  • Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses
  • The company is in debt and has limited leeway for investment
  • With a 2018 P/E ratio at 23.42 times the estimated earnings, the company operates at rather significant levels of earnings multiples.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 402.85 EUR
Eurofins Scientific S.E. : A technical turn-around configuration

Jordan Dufee
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (€)
Sales 2019 4 494 M
EBIT 2019 530 M
Net income 2019 325 M
Debt 2019 2 978 M
Yield 2019 0,94%
P/E ratio 2019 21,44
P/E ratio 2020 16,60
EV / Sales 2019 2,12x
EV / Sales 2020 1,95x
Capitalization 6 542 M
Upcoming event on EUROFINS SCIENTIFIC S.E.
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 12
Average target price 439 €
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Gilles G. Martin Chairman & Chief Executive Officer
Laurent Lebras Director-Group Finance & Administration
Andreas König Chief Information Officer
Yves-Loïc Martin Non-Executive Director
Valérie Hanote Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
EUROFINS SCIENTIFIC S.E.15.52%7 450
WORLDPAY INC60.63%38 208
FISERV INC22.85%35 429
FIRST DATA CORP58.66%25 396
GLOBAL PAYMENTS53.83%24 807
CINTAS CORPORATION38.56%24 203